BioCorRx, Inc. v. VDM Biochemicals, Inc. (2023) 96 Cal.App.5th 841
Insofar as defendant's cross-complaint was based on plaintiff's press releases about a treatment it was developing for opioid overdose, the claims fell within the CCP 425.17(c) exemption from the Anti-SLAPP statute. Contrary to plaintiff's argument, the fact that over recent years it obtained and spent most of its money on research and development did not show that it was not… Read More